These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

132 related articles for article (PubMed ID: 3047334)

  • 1. A randomized comparison of haloperidol plus dexamethasone versus prochlorperazine plus dexamethasone in preventing nausea and vomiting in patients receiving chemotherapy for breast cancer.
    Silvey L; Carpenter JT; Wheeler RH; Lee J; Conolley C
    J Clin Oncol; 1988 Sep; 6(9):1397-400. PubMed ID: 3047334
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Ondansetron compared with dexamethasone and metoclopramide as antiemetics in the chemotherapy of breast cancer with cyclophosphamide, methotrexate, and fluorouracil.
    Levitt M; Warr D; Yelle L; Rayner HL; Lofters WS; Perrault DJ; Wilson KS; Latreille J; Potvin M; Warner E
    N Engl J Med; 1993 Apr; 328(15):1081-4. PubMed ID: 8455665
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Pentobarbital's effect in a combination antiemetic regimen for cisplatin induced nausea and vomiting.
    Wheelock JB
    J Miss State Med Assoc; 1989 Jan; 30(1):5-8. PubMed ID: 2647995
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Double-blind randomized cross-over trial of dexamethasone and prochlorperazine as anti-emetics for cancer chemotherapy.
    Goldstein D; Levi JA; Woods RL; Russell J; Morgan J; Kerestes Z
    Oncology; 1989; 46(2):105-8. PubMed ID: 2652018
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Provision of information by pharmacists regarding the effective timing of co-administration of first-generation serotonin receptor antagonists and dexamethasone for chemotherapy-induced nausea and vomiting in patients receiving Doxorubicin and cyclophosphamide chemotherapy for breast cancer].
    Nomura H; Kawakami H; Shimizu H; Imi K; Ito H; Isaka H; Shinohara T; Nagai S; Imoto S
    Gan To Kagaku Ryoho; 2012 Jan; 39(1):75-9. PubMed ID: 22241355
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A randomized study of aprepitant, ondansetron and dexamethasone for chemotherapy-induced nausea and vomiting in Chinese breast cancer patients receiving moderately emetogenic chemotherapy.
    Yeo W; Mo FK; Suen JJ; Ho WM; Chan SL; Lau W; Koh J; Yeung WK; Kwan WH; Lee KK; Mok TS; Poon AN; Lam KC; Hui EK; Zee B
    Breast Cancer Res Treat; 2009 Feb; 113(3):529-35. PubMed ID: 18327706
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Antiemetic efficacy of dexamethasone. Randomized, double-blind, crossover study with prochlorperazine in patients receiving cancer chemotherapy.
    Markman M; Sheidler V; Ettinger DS; Quaskey SA; Mellits ED
    N Engl J Med; 1984 Aug; 311(9):549-52. PubMed ID: 6379459
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Use of dexamethasone as an antiemetic in patients with breast cancer treated with the CMF regimen].
    Domaradzka-Woźniak A; Wojtacki J; Dziewulska-Bokiniec A
    Przegl Lek; 1994; 51(5):203-5. PubMed ID: 7938648
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Information provided by pharmacists regarding the effective timing of the coadministration of first-generation serotonin receptor antagonists and dexamethasone for chemotherapy-induced nausea and vomiting in patients receiving Doxorubicin and cyclophosphamide chemotherapy for breast cancer - the second report].
    Nomura H; Kawakami H; Usui H; Suzuki S; Imoto S; Saito S
    Gan To Kagaku Ryoho; 2014 Sep; 41(9):1129-33. PubMed ID: 25248897
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Lorazepam: a randomized, double-blind, crossover study of a new antiemetic in patients receiving cytotoxic chemotherapy and prochlorperazine.
    Bishop JF; Olver IN; Wolf MM; Matthews JP; Long M; Bingham J; Hillcoat BL; Cooper IA
    J Clin Oncol; 1984 Jun; 2(6):691-5. PubMed ID: 6374058
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Comparison of prochlorperazine and lorazepam antiemetic regimens in the control of postchemotherapy symptoms.
    Simms SG; Rhodes VA; Madsen RW
    Nurs Res; 1993; 42(4):234-9. PubMed ID: 8337162
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Aprepitant versus dexamethasone for preventing chemotherapy-induced delayed emesis in patients with breast cancer: a randomized double-blind study.
    Roila F; Ruggeri B; Ballatori E; Del Favero A; Tonato M
    J Clin Oncol; 2014 Jan; 32(2):101-6. PubMed ID: 24323030
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Dexamethasone, granisetron, or both for the prevention of nausea and vomiting during chemotherapy for cancer.
    Italian Group for Antiemetic Research
    N Engl J Med; 1995 Jan; 332(1):1-5. PubMed ID: 7990859
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Anticipatory vomiting in women receiving cyclophosphamide, methotrexate, and 5-FU (CMF) adjuvant chemotherapy for breast carcinoma.
    Wilcox PM; Fetting JH; Nettesheim KM; Abeloff MD
    Cancer Treat Rep; 1982 Aug; 66(8):1601-4. PubMed ID: 7049385
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Incidence of emesis in outpatients on chemotherapy for breast cancer and the clinical efficacy of ondansetron hydrochloride tablets].
    Ishida T; Kusaba T; Hayakawa H
    Gan To Kagaku Ryoho; 2002 May; 29(5):723-8. PubMed ID: 12040676
    [TBL] [Abstract][Full Text] [Related]  

  • 16. High efficacy of a single oral dose of ondansetron 8 mg versus a metoclopramide regimen in the prevention of acute emesis induced by fluorouracil, doxorubicin and cyclophosphamide (FAC) chemotherapy for breast cancer.
    Bosnjak SM; Nesković-Konstantinović ZB; Radulović SS; Susnjar S; Mitrovi LB
    J Chemother; 2000 Oct; 12(5):446-53. PubMed ID: 11128567
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Persistence of efficacy of three antiemetic regimens and prognostic factors in patients undergoing moderately emetogenic chemotherapy. Italian Group for Antiemetic Research.
    J Clin Oncol; 1995 Sep; 13(9):2417-26. PubMed ID: 7666102
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Efficacy of triplet regimen antiemetic therapy for chemotherapy-induced nausea and vomiting (CINV) in bone and soft tissue sarcoma patients receiving highly emetogenic chemotherapy, and an efficacy comparison of single-shot palonosetron and consecutive-day granisetron for CINV in a randomized, single-blinded crossover study.
    Kimura H; Yamamoto N; Shirai T; Nishida H; Hayashi K; Tanzawa Y; Takeuchi A; Igarashi K; Inatani H; Shimozaki S; Kato T; Aoki Y; Higuchi T; Tsuchiya H
    Cancer Med; 2015 Mar; 4(3):333-41. PubMed ID: 25533447
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [A randomized controlled trial of acute and delayed cisplatin-induced emesis with metoclopramide, dexamethasone and prochlorperazine].
    Nino S; Umehara H; Inoue I; Tamura T; Sasaki Y; Sakurai M; Shinkai T; Eguchi K; Saijo N; Suemasu K
    Gan To Kagaku Ryoho; 1987 Oct; 14(10):2881-4. PubMed ID: 3310905
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Comparable safety and antiemetic efficacy of a brief (30-second bolus) intravenous granisetron infusion and a standard (15-minute) intravenous ondansetron infusion in breast cancer patients receiving moderately emetogenic chemotherapy.
    Perez EA; Lembersky B; Kaywin P; Kalman L; Yocom K; Friedman C
    Cancer J Sci Am; 1998; 4(1):52-8. PubMed ID: 9467047
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.